HF 0420
Alternative Names: HF0420; OligotropinLatest Information Update: 04 Nov 2017
At a glance
- Originator Loyola University Chicago
- Developer Hunter-Fleming; Loyola University Chicago
- Class Glycosaminoglycans; Heparins; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peripheral nervous system diseases
- Discontinued Alzheimer's disease; CNS trauma; Stroke
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Peripheral-nervous-system-diseases(Prevention) in Italy (PO)
- 14 Oct 2009 Newron returns HF 0420 rights to inventor, Umberto Cornelli of Loyola University
- 05 Apr 2006 This compound is still in active development for Alzheimer's disease